Covered recipient · General Payments record
JENNIFER B SHOLES
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,021.58
- Reported across 119 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $902.39 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $383.46 | 14 |
| REVANCE THERAPEUTICS, INC. | $221.75 | 4 |
| Lilly USA, LLC | $145.65 | 10 |
| Abbott Laboratories | $73.20 | 3 |
| Galderma Laboratories, L.P. | $42.68 | 2 |
| Novo Nordisk AS | $35.65 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20182019202020222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $24.18 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125085805 | CMS |
| Abbott Laboratories | $24.68 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125085807 | CMS |
| Abbott Laboratories | $24.34 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125085809 | CMS |
| ABBVIE INC. | $22.64 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090978 | CMS |
| ABBVIE INC. | $26.35 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090980 | CMS |
| ABBVIE INC. | $29.11 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090982 | CMS |
| ABBVIE INC. | $25.85 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090984 | CMS |
| ABBVIE INC. | $27.51 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090986 | CMS |
| ABBVIE INC. | $6.44 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090988 | CMS |
| ABBVIE INC. | $25.87 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090990 | CMS |
| ABBVIE INC. | $29.38 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090992 | CMS |
| ABBVIE INC. | $32.00 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090994 | CMS |
| ABBVIE INC. | $93.95 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090996 | CMS |
| ABBVIE INC. | $4.82 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106090998 | CMS |
| ABBVIE INC. | $26.96 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106091000 | CMS |
| ABBVIE INC. | $6.12 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106091002 | CMS |
| ABBVIE INC. | $26.46 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106091004 | CMS |
| Galderma Laboratories, L.P. | $23.91 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145328032 | CMS |
| Galderma Laboratories, L.P. | $18.77 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145328034 | CMS |
| Lilly USA, LLC | $6.13 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135041545 | CMS |
| Lilly USA, LLC | $17.13 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135062247 | CMS |
| Lilly USA, LLC | $17.28 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135041225 | CMS |
| Lilly USA, LLC | $25.09 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135041547 | CMS |
| Lilly USA, LLC | $14.59 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135058032 | CMS |
| Lilly USA, LLC | $18.09 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135041549 | CMS |
| Lilly USA, LLC | $6.45 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135062249 | CMS |
| Lilly USA, LLC | $22.67 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135062245 | CMS |
| Lilly USA, LLC | $12.36 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135058260 | CMS |
| Lilly USA, LLC | $5.86 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135041223 | CMS |
| Novo Nordisk Inc | $18.37 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096927252 | CMS |
| Novo Nordisk Inc | $17.28 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097162123 | CMS |
| REVANCE THERAPEUTICS, INC. | $77.37 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147929209 | CMS |
| REVANCE THERAPEUTICS, INC. | $54.68 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147929211 | CMS |
| REVANCE THERAPEUTICS, INC. | $13.45 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147929213 | CMS |
| REVANCE THERAPEUTICS, INC. | $76.25 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147929215 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.